Bellerophon announces positive top-line results from cohort 2 of phase 2/3 study of inopulse

Bellerophon announces positive top-line results from cohort 2 of phase 2/3 study of inopulse® for treatment of pulmonary hypertension associated with interstitial lung disease.bellerophon therapeutics inc - inopulse was well-tolerated with no safety concerns.bellerophon therapeutics - intends to initiate pivotal phase 3 in q1 of 2020 for inopulse.bellerophon therapeutics inc - entered into an agreement for a $10 million convertible financing facility.bellerophon therapeutics - new capital extends cash runway into 2021.
BLPH Ratings Summary
BLPH Quant Ranking